fb-101
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2019 (NCT04165837)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase V-ABLINHIBITOR
ABL inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07126704 | Phase 1 | Nov 30, 2025 | 1ST Biotherapeutics, Inc. |
| NCT04165837 | Phase 1 | Oct 14, 2019 | 1ST Biotherapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 1ST Biotherapeutics, Inc. | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1